The medication is commonly used to help with managing symptoms related to acute psychomotor distress, including uncontrolled aggression and severe restlessness, in clinical settings that involve acute or unstable symptom patterns. The medication is considered relevant for easing symptoms related to the prevention and treatment of post-operative nausea and vomiting (PONV), and for its role in supporting general anesthesia as an anesthesia adjuvant and premedicant.

The medication may assist with providing supportive relief to ease the distress and contribute to maintaining a sense of stability, which supports the patient during difficult episodes by easing distress. The medication is used across therapeutic domains where short-term symptom management is appropriate, and helps patients cope more steadily and is applied during phases of increased distress or discomfort.

“Droperidol is commonly used to help with managing symptoms that create noticeable physiological strain in acute care settings.”

Quick Fact: Relief for Acute Distress

Quick Fact: Relief for Acute Psychomotor Distress, Post-Operative Nausea, and Pre-Procedural Apprehension. This supportive use is considered relevant for children aged two years and older as well as adults.

Regulatory References

1. New Zealand Medsafe Data Sheet on Droperidol

Eligibility and Contraindications for Дроперидол (Droperidol)

Official regulatory guidelines define strict population eligibility criteria for Droperidol, primarily due to its potential effects on the heart's electrical rhythm.

Absolute Contraindications (Must Not Use)

Droperidol is explicitly contraindicated in patients who exhibit or have a history of the following conditions:

• Cardiac Risks: Known or suspected QT interval prolongation (a specific risk to heart rhythm), congenital Long QT Syndrome, or clinically significant bradycardia (slow heart rate, typically less than 55 beats per minute).
• Electrolyte Imbalances: Uncorrected low blood levels of potassium (Hypokalaemia) or magnesium (Hypomagnesaemia).
• Neurological/Endocrine: Parkinson's Disease, Phaeochromocytoma, or severe Hypersensitivity to Droperidol or related butyrophenone drugs.

Age and Special Population Restrictions

Population Group	Official Eligibility Status
Children under 2 years	Not Recommended (Safety and efficacy not established).
Children geq 2 years to Adults	Approved for use in labeled indications.
Geriatric Patients	Restricted Use: Requires a reduced initial dose.
Hepatic/Renal Impairment	Restricted Use: Requires caution due to impact on drug clearance.

Pregnancy and Lactation: Use during pregnancy is only advised if the potential benefit justifies the potential risk to the fetus. Caution is recommended for breastfeeding mothers.

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Droperidol across critical pharmacodynamic and pharmacokinetic domains.

Contraindicated Combinations and Cardiac Risk Co-administration with any medicinal product known to prolong the QT interval is formally contraindicated due to the documented risk of serious ventricular arrhythmias, including Torsades de pointes. This restriction is applicable to patients with known or suspected congenital Long QT Syndrome. Caution is also required when used with medications that induce electrolyte imbalance, such as potassium-wasting diuretics or laxatives, as the resulting hypokalemia or hypomagnesemia may indirectly heighten the cardiac risk.

Pharmacodynamic Interactions Concomitant use with other Central Nervous System (CNS) depressant drugs, including general anesthetics and opioids, results in additive or potentiating effects (e.g., increased sedation). Consumption of alcoholic beverages must be avoided for the same reason. Furthermore, Droperidol may antagonize the effects of Dopamine Agonists, such as Levodopa, and is officially documented to reduce the pressor effect of Epinephrine.

Metabolic Considerations The elimination of Droperidol involves the cytochrome P450 iso-enzymes CYP1A2 and CYP3A4. Co-administration with strong inhibitors of these enzymes could decrease the rate of Droperidol metabolism and prolong its pharmacological action, a circumstance noted in regulatory labeling that requires necessary consideration.

Droperidol's pharmacological action is primarily mediated by its high-affinity antagonism of dopamine D2 receptors within the central nervous system. This molecular interaction competitively blocks the binding of the endogenous neurotransmitter dopamine, leading to a modulation of dopaminergic pathways. This mechanism is most pronounced in the mesolimbic system and the chemoreceptor trigger zone (CTZ) of the brainstem, resulting in a reduction of signal transduction through the D2 receptor pathway.

Additionally, droperidol exhibits antagonistic activity at central and peripheral alpha1-adrenergic receptors. Blockade of these receptors inhibits the vasoconstrictive effects typically mediated by norepinephrine. This peripheral vascular effect modifies systemic circulatory dynamics. The compound also demonstrates a lesser binding affinity toward specific histamine H1 and serotonin 5- HT2 receptors, and modulates the activation of GABA A and neuronal nicotinic acetylcholine receptors, contributing to its broad influence on neuronal excitability and central nervous system activity.

How Droperidol Is Administered

Droperidol is provided exclusively as a sterile injectable solution (2.5 mg/ mL) for parenteral use, meaning it is administered by Intravenous (IV) or Intramuscular (IM) injection. The medication is intended for short-term use only in acute, supervised clinical settings.

---

Administration Scope and Dosing

Entity	Official Instruction
Route of Administration	Must be given via IV or IM route. IV injection should be administered slowly, typically over at least one minute.
Preparation	The solution must be visually inspected prior to use. Dilution is not required for administration.
Adult Dosing (PONV)	For prevention and treatment of post-operative nausea and vomiting (PONV), the IV dose typically ranges from 0.625 mg to 1.25 mg, or a maximum initial dose of 2.5 mg IM or slow IV.
Adult Dosing (Agitation)	For acute management of severe agitation, the initial dose is typically 2.5 mg to 5 mg IM or slow IV. The maximum dose should not exceed 20 mg in any 24-hour period.

---

Frequency and Special Administration Rules

Repeat doses for PONV may be administered every 6 hours as required, while additional doses for acute agitation require a minimum interval of 20 minutes. When used alongside other central nervous system depressants, such as opioids, the dose of the co-administered agent must be reduced.

Population-Specific Adjustments The initial dose must be appropriately reduced for older adults (over 65 years) and patients with impaired renal or hepatic function. For pediatric patients (2 to 12 years), the maximum initial dose is 0.1 mg/ kg, not to exceed 2.5 mg. Use in children under two years is not recommended.

Research Evidence / Overview of Studies for Дроперидол

Droperidol has been the subject of clinical evaluations reviewed by regulatory bodies, primarily focusing on its uses in acute medical settings. The research landscape is characterized by types of trials, including controlled comparisons and systematic reviews, which help contextualize its use as a medication studied for specific acute and perioperative symptom patterns.

---

Evidence for Use in Acute Agitation and Behavioral Distress

Research examined outcomes describing episodic or acute changes, specifically monitoring the time required for participants to reach a desired level of calmness, which is a key measured outcome in conditions characterized by acute or disruptive episodes. The documented observations for acute sedation patterns were primarily drawn from short-term assessments within the first hour of administration. Trials reported measurements of the speed at which participants transitioned from an agitated state to a sedated state. Long-term effects are not fully established, as follow-up durations were limited, reflecting the acute context under which the research was conducted.

---

Evidence for Use in Preventing Post-Operative Nausea and Vomiting

Droperidol was studied for its potential role in the prevention and monitoring of outcomes related to physical discomfort following surgery, specifically Post-Operative Nausea and Vomiting (PONV). The research includes a number of Randomized Controlled Trials (RCTs) and meta-analyses. Studies monitored the frequency of symptoms reported in the observed populations across defined time intervals, tracking changes measured during the study period. Findings describe patterns observed in the trials related to the frequency of symptoms reported, both in the early hours and across the subsequent 24-hour window.

---

Research in Special Populations

Droperidol was evaluated in studies across different age groups. Research describes that the primary evidence base for acute agitation is for adult populations. Research has explored the use of droperidol in older adults (aged 65 and over), where studies have described patterns of use for monitoring episodes where symptoms become more noticeable. Data are still emerging for its use in pediatric populations, and evidence for acute agitation in adolescents remains less developed than the adult data.

Key Studies & References

1. Droperidol: Medsafe Data Sheet (Pan Pharma Injection)

Common questions about Дроперидол (FAQ)

Q: How quickly does the effect of Дроперидол usually start?

Official information indicates that the initial effects, such as tranquilization and sedation, typically begin rapidly after administration. These noticeable effects usually last for about 2 to 4 hours, though a change in alertness may be present for up to 12 hours.

---

Q: Are there any common over-the-counter medicines that interact with Дроперидол?

Regulatory documents advise that the medicine can have additive or potentiating effects when combined with other drugs that depress the Central Nervous System (CNS). This includes certain common over-the-counter (OTC) products, such as some cold medicines or specific antihistamines. For this reason, official labeling emphasizes the need for caution when co-administering such agents.

---

Q: Can a patient drive or operate machinery after receiving Дроперидол?

Due to common side effects like sedation and drowsiness, regulatory labeling indicates that patients are typically advised to avoid hazardous activities that require mental alertness and motor coordination. It is generally recommended to avoid driving or operating complex machinery until the full effects of the medicine are completely known and resolved.

---

Q: Does the official information mention any specific foods to avoid with Дроперидол?

Official product information explicitly states that alcoholic beverages must be avoided because consumption increases the risk of enhanced sedation. However, the regulatory documents do not include specific warnings regarding the avoidance of particular foods.

---

Q: Does taking certain supplements or herbal remedies interact with Дроперидол?

Studies and official information indicate that the medicine is processed and eliminated by specific enzymes, CYP1A2 and CYP3A4. Therefore, co-administration with certain supplements or herbal remedies that inhibit or block these enzymes could potentially prolong the medicine’s pharmacological action. Caution is also advised regarding products that could affect the body’s electrolyte balance (potassium and magnesium levels).

---

Q: What other names is Дроперидол known by internationally?

In addition to the generic name Droperidol, the drug is recognized internationally by various brand names, including Inapsine (historically used in the US), Droleptan (used in France), and Xomolix (used in some parts of Europe), among others.

---

Q: Does the package insert mention a risk of seizures with Дроперидол?

Regulatory documents describe a risk that the medicine may precipitate acute manifestations of epilepsy. Official labeling advises that administration requires caution in patients with known susceptibility to seizures.

---

Q: What specific warnings are given about using Дроперидол with antidepressant medications?

Official drug labels describe that the medicine requires extreme caution alongside certain antidepressants, such as tricyclic antidepressants. This is because many antidepressants, like Droperidol, are known to prolong the QT interval of the heart, which increases the combined risk of serious cardiac arrhythmias.

---

Q: Is the use of Дроперидол restricted in certain countries?

Following regulatory action, including the issuance of a Boxed Warning regarding potential cardiac risks, the use of the medicine was significantly curtailed and restricted to specific indications or doses in various jurisdictions, notably in the United States.

---

Q: Is Дроперидол commonly used in emergency medicine settings?

The medicine is designed as an acute care agent and is provided exclusively as an injectable solution for use in acute, supervised clinical settings. This context of use aligns with its rapid onset and indications for the quick control of severe symptoms.

---

Q: Why is there a Boxed Warning (Black Box) associated with Дроперидол?

The medicine carries a Boxed Warning on its US regulatory labeling due to the documented risk of serious ventricular arrhythmias, including Torsades de pointes, and the potential for QT prolongation (a change in the heart's electrical rhythm). This warning is mandated to highlight the necessary cardiac precautions and restrictions for use.

---

Q: What is neuroleptic malignant syndrome, and is it a risk with Дроперидол?

Neuroleptic Malignant Syndrome (NMS) is described in official documents as an uncommon but serious adverse reaction associated with this class of medication. NMS is a rare condition characterized by fever, muscular rigidity, altered mental status, and evidence of autonomic instability, which is listed as a potential risk.

---

Q: What does 'QT prolongation' mean in relation to Дроперидол?

QT prolongation refers to an abnormal change in the heart’s electrical cycle, which is a specific risk associated with this medicine. Regulatory information indicates that QT prolongation makes the patient vulnerable to life-threatening heart rhythm disturbances, such as Torsades de pointes. This is why the medicine is contraindicated in patients with a history of heart rhythm issues.

---

Q: How does the official literature describe the feeling or experience of taking Дроперидол?

The general role of the drug is to provide rapid tranquilization and sedation. The official literature focuses on measuring therapeutic outcomes and potential side effects, such as drowsiness and dizziness, rather than a subjective description of the patient’s overall feeling or experience.

---

Q: Are there any specific blood tests required when receiving Дроперидол?

Official guidelines state that the medicine is absolutely contraindicated in patients with uncorrected low levels of potassium (Hypokalaemia) or magnesium (Hypomagnesaemia). Therefore, regulatory guidelines emphasize that the patient's blood electrolyte levels should be known and addressed prior to administration to help reduce the risk of serious heart arrhythmias.

---

Q: Is Дроперидол used for pain management as a primary treatment?

The medicine's primary roles are as an antiemetic, a sedative, and an Anesthesia Adjuvant (a drug used to assist anesthesia). While it may be used in combination with opioids, which are pain medications, its primary function is not described as being a stand-alone, first-line treatment for pain management.

---

Q: Can Дроперидол cause changes in body temperature?

Official adverse event information lists Neuroleptic Malignant Syndrome (NMS) as an uncommon but documented risk. NMS is a serious condition that is characterized by, among other symptoms, severe, life-threatening changes in body temperature.

---

Q: What is the recommended period for observation after receiving Дроперидол?

Due to the risk of serious cardiac events and other potential side effects, regulatory information emphasizes that patients must be monitored closely following administration. Specific observation periods are generally determined by the supervising clinical staff, who follow official protocols for post-injection monitoring.

How to Store and Dispose of Дроперидол?

The storage and disposal requirements for Droperidol (Дроперидол) injectable solution are strictly defined in regulatory labeling to maintain potency and ensure safety. This section outlines the official, mandatory storage and disposal rules.

Official Storage Requirements

Storage Component	Mandatory Instruction
Temperature	Store the unopened product at Controlled Room Temperature (20 to 25 C).
Light Protection	Store in the original package to protect from light.
Solution Stability	For single use only. Any unused solution must be discarded immediately after opening.
Visual Inspection	The solution must be clear and colorless and free from visible particles before use.
Child Safety	Keep out of the sight and reach of children.

Official Disposal Instructions

To dispose of unused or expired Droperidol, all waste material must be managed in accordance with local regulations. Do not flush the product down a toilet or throw it in the household trash unless specifically instructed to do so by a healthcare professional or regulatory body.